FARA, Adverum Biotechnologies, Catabasis Pharmaceuticals and Horizon Pharma plc
Join Nasdaq’s Live Broadcast on #GivingTuesday
New York- November 29- The Friedreich’s Ataxia Research Alliance (FARA), Adverum Biotechnologies, Catabasis Pharmaceuticals (Nasdaq:CATB), and Horizon Pharma plc mark #GivingTuesday on November 29 by teaming up for a live informational Facebook broadcast from Nasdaq MarketSite Entering its fifth year, #GivingTuesday is a global day of giving fueled by the power of social media and collaboration.
FARA’s Executive Director, Jennifer Farmer, will moderate a panel, including select Nasdaq-listed companies with product candidates focused on Friedreich’s ataxia, to raise awareness of this rare disease and the ongoing work to develop treatments. The panel will discuss different approaches to treatment development for FA including small molecules, biologics and gene therapy, and how these can be synergistic. They will also highlight ways in which advocacy organizations and pharmaceutical organizations have partnered to expedite research. The panel will include:
- Amber Salzman, PhD- President & CEO at Adverum Biotechnologies, Inc.
- Andrew Nichols, PhD- Chief Scientific Officer at Catabasis
- Jeffrey Sherman, M.D., FACP-Executive Vice President, Research and Development and Chief Medical Officer at Horizon Pharma plc.
Read the full press release HERE.